Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis
Frontiers in Immunology, 2019 Objective: Sporadic Inclusion Body Myositis (sIBM) is an inflammatory myopathy (IIM) without a specific diagnostic biomarker until autoantibodies to the cytosolic 5′-nucleotidase 1A (NT5c1A/Mup44) were reported.
Adam Amlani +11 more
doaj +1 more source
Betekintés az idiopathiás inflammatorikus myopathiában szenvedő betegek gyógytornájába | Insight into the training of patients with idiopathic inflammatory myopathy [PDF]
, 2016 Absztrakt Idiopathiás inflammatorikus myopathiában szenvedő betegeknél a jelenleg alkalmazott gyógyszeres kezelés mellett izomkárosodás és egészségromlás alakul ki.
Váncsa, Andrea
core +1 more source
Biomarkers in Inflammatory Myopathies – An Expanded Definition [PDF]
, 2019 Biomarkers as parameters of pathophysiological conditions can be of outmost relevance for inflammatory myopathies. They are particularly warranted to inform about diagnostic, prognostic, and therapeutic questions.
Benveniste, Olivier +2 more
core +3 more sources
A practical approach to the patient presenting with dropped head [PDF]
, 2016 Head drop, or having a dropped head, is an uncommon condition in which patients present with a disabling inability to lift their head. It may arise in many neurological conditions that can be divided into those with neuromuscular weakness of neck ...
Demicoli, Marija, Marsh, Eleanor A.
core +1 more source
Concomitant occurrence of FXTAS and clinically defined sporadic inclusion body myositis: report of two cases. [PDF]
, 2017 This report describes unique presentations of inclusion body myositis (IBM) in two unrelated patients, one male and one female, with genetically and histologically confirmed fragile X-associated tremor/ataxia syndrome (FXTAS).
Bolitho, Samuel J +11 more
core +2 more sources
Autoantibodies Produced at the Site of Tissue Damage Provide Evidence of Humoral Autoimmunity in Inclusion Body Myositis [PDF]
, 2012 Inclusion body myositis (IBM) belongs to a group of muscle diseases known as the inflammatory myopathies. The presence of antibody-secreting plasma cells in IBM muscle implicates the humoral immune response in this disease.
Amato, Anthony A. +12 more
core +4 more sources
Immune‐Driven Expression in Inclusion Body Myositis With T‐Cell Large Granular Lymphocytic Leukemia
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objectives T‐cell large granular lymphocytic leukemia (T‐LGLL), reported in up to 58% of inclusion body myositis (IBM) patients, is a rare leukemia of cytotoxic or less commonly helper T cells. The range of myopathies in T‐LGLL and the impact of coexisting T‐LGLL in IBM are not well understood. Our objectives are to investigate the spectrum of
Pannathat Soontrapa +10 more
wiley +1 more source
Asymptomatic hyper-creatine-kinase-emia as sole manifestation of inclusion body myositis
Neurology International, 2013 Sporadic inclusion body myositis (sIBM) usually manifests with painless weakness of the hand, finger and hip flexors. Absence of symptoms or signs, but mild hyper-CK-emia as the sole manifestation of IBM, has not been reported. We report the case of a 73-
Josef Finsterer +2 more
doaj +1 more source
Unravelling inclusion body myositis using a patient‐derived fibroblast model
Journal of Cachexia, Sarcopenia and Muscle, 2023 Background Inclusion body myositis (IBM) is an inflammatory myopathy clinically characterized by proximal and distal muscle weakness, with inflammatory infiltrates, rimmed vacuoles and mitochondrial changes in muscle histopathology.
Judith Cantó‐Santos +18 more
doaj +1 more source
Serum levels of matrix metalloproteinases-2 and-9 and their tissue inhibitors in inflammatory neuromuscular disorders [PDF]
, 2006 We monitored serum levels of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) before and during intravenously applied immunoglobulin (IVIG) therapy in 33 patients with chronic immune-mediated neuropathies and myopathies and 15 ...
B.G.H. Schoser +15 more
core +1 more source